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RESULTS

OBJECTIVE
The purpose of this medication use evaluation (MUE) was to evaluate a
pharmacy managed vancomycin dosing protocol for patients on CRRT
patients in a community hospital.

BACKGROUND
• Vancomycin is a key antimicrobial agent for the treatment of Grampositive bacterial infections.2
• Medication dosing in patients requiring continuous renal replacement
therapy (CRRT) for acute or acute on chronic renal failure has been a
focus in literature in the last decade.
• It is known that the type of CRRT technique, rate of volume removed,
and interruptions of therapy can make dosing in this patient population
challenging.
• In 2020, Infectious Diseases Society of America published clinical
practice guidelines for the monitoring of vancomycin, outlining
vancomycin dosing in CRRT.1
• Current institution protocols dose vancomycin in CRRT/CVVH by giving a
loading dose of 20 mg/kg (max: 2,500 mg) and give subsequent doses
based on random vancomycin levels at the pharmacist’s discretion.

METHODS
• Study Design: Retrospective chart review was used to identify
critically ill adult patients admitted who received two or more
doses of intravenous vancomycin therapy while on CRRT between
January 7, 2018 and May 24, 2020.
• Institutional Review Board (IRB) Approval: Parkview Health IRB
approved this quality improvement project.
• Inclusion criteria: Patients who received two or more doses of
intravenous vancomycin whilst on CRRT.
• Exclusion criteria: Patients were excluded if they were receiving
hemodialysis prior to or during admission, had multiple instances
of CRRT during the admission, or had greater than 8 vancomycin
levels drawn.
• Primary outcome: The primary outcome was percent of patients
with a therapeutic vancomycin level at any point of their admission
based on indication for use

OUTCOMES

Table 1: Baseline Demographics

Characteristics
Age, Years, Average (SD)
Male, n, (%)
Hospital LOS, Days, Average (SD)
ICU LOS, Days, Average (SD)
Vancomycin Orders per patient, Average
(SD)
SCr prior to CRRT, mg/dL, Average (SD)
Albumin prior to CRRT, g/dL, Average (SD)

Other
Indications
n= 7

Sepsis
n= 42

Pneumonia
n= 13

64.6 (11.89)
24 (57)
11.6 (7.99)
8.83 (6.08)

67.2 (11.36)
5 (38)
11.1 (9.78)
9.11 (9.31)

3.36 (2.00)

3.85 (2.41)

8.29 (10.70)

5.38 (3.33)
2.8 (0.62)

3.6 (1.45)
2.76 (0.82)

4.22 (2.07)
2.47 (0.49)

Figure 1: Vancomycin Treatment Indication

63.3 (16.88)
4 (57)
23.4 (16.50)
15.7 (10.22)

• The indication for vancomycin was sepsis in 68% of cases. CRRT was
initiated in 71% of patients after a vancomycin administration.
Patients received an average of 4 vancomycin doses during
admission.
• 29% of total patients achieved a therapeutic vancomycin level during
admission. Of those with a therapeutic level, 67% were being treated
for sepsis with a goal of 15 to 20 mcg/mL
• 71% of total patients failed to achieve a therapeutic vancomycin level
during admission.
• Of patients without a therapeutic level, 45% received 2 doses and
30% received 3 doses.
• On average, patients without a therapeutic level only had 1 level
drawn and 34% of patients had no levels drawn during therapy.

DISCUSSION & CONCLUSIONS

Figure 2: Percent of Patients Reaching Therapeutic Goals by Number of Levels Drawn

• The evaluation of a pharmacy managed vancomycin dosing protocol
on CRRT patients was inconclusive due to the duration of
vancomycin therapy.
• Patient culture data was collected and assessed to determine if
vancomycin therapy was indicated. The cultures included within our
research were Staphylococcus aureus (MRSA) or Staphylococcus
with a positive mecA (methicillin resistance) gene and Enterococcus
faecalis.
• Based on culture results, it can be presumed that vancomycin was
initiated for empiric therapy and then de-escalated in most cases.
• In patients that did not obtain a therapeutic level, the number of
vancomycin doses received was less than required to reach steady
state.
• A future direction to assess the vancomycin dosing protocol would
be to evaluate patients with a confirmed indication for prolonged
vancomycin therapy.
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